BR112015006051A2 - usos inéditos - Google Patents

usos inéditos

Info

Publication number
BR112015006051A2
BR112015006051A2 BR112015006051A BR112015006051A BR112015006051A2 BR 112015006051 A2 BR112015006051 A2 BR 112015006051A2 BR 112015006051 A BR112015006051 A BR 112015006051A BR 112015006051 A BR112015006051 A BR 112015006051A BR 112015006051 A2 BR112015006051 A2 BR 112015006051A2
Authority
BR
Brazil
Prior art keywords
unpublished
pruritus
abstract
combinations
compound
Prior art date
Application number
BR112015006051A
Other languages
English (en)
Inventor
Emiliangelo Ratti
Michael Trower
Original Assignee
Nerre Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nerre Therapeutics Ltd filed Critical Nerre Therapeutics Ltd
Publication of BR112015006051A2 publication Critical patent/BR112015006051A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Electrically Operated Instructional Devices (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

resumo “usos inéditos” esta invenção diz respeito ao uso inédito do composto (i) ou sais farmaceuticamente aceitáveis deste e composições farmacêuticas contendo-os para o tratamento de prurite e às combinações para um uso como este.
BR112015006051A 2012-10-11 2013-10-09 usos inéditos BR112015006051A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261712499P 2012-10-11 2012-10-11
PCT/EP2013/071093 WO2014057003A1 (en) 2012-10-11 2013-10-09 Novel uses

Publications (1)

Publication Number Publication Date
BR112015006051A2 true BR112015006051A2 (pt) 2017-07-04

Family

ID=49322388

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015006051A BR112015006051A2 (pt) 2012-10-11 2013-10-09 usos inéditos

Country Status (24)

Country Link
US (3) US9603849B2 (pt)
EP (2) EP3597192A1 (pt)
JP (2) JP6815728B2 (pt)
KR (1) KR102202481B1 (pt)
CN (1) CN104703603A (pt)
AU (1) AU2013328695B9 (pt)
BR (1) BR112015006051A2 (pt)
CA (1) CA2884454C (pt)
CY (1) CY1122313T1 (pt)
DK (1) DK2906219T3 (pt)
EA (1) EA201590364A1 (pt)
ES (1) ES2750662T3 (pt)
HK (1) HK1211486A1 (pt)
HR (1) HRP20191955T1 (pt)
HU (1) HUE046508T2 (pt)
IL (1) IL237636B (pt)
LT (1) LT2906219T (pt)
MX (1) MX362879B (pt)
PL (1) PL2906219T3 (pt)
PT (1) PT2906219T (pt)
RS (1) RS59470B1 (pt)
SG (1) SG11201501867UA (pt)
SI (1) SI2906219T1 (pt)
WO (1) WO2014057003A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201501867UA (en) * 2012-10-11 2015-04-29 Nerre Therapeutics Ltd Novel uses
US8906951B1 (en) 2013-06-24 2014-12-09 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
US9198898B2 (en) 2013-06-24 2015-12-01 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
AU2016384267B2 (en) * 2016-01-08 2022-02-03 Nerre Therapeutics Limited Orvepitant for the treatment of chronic cough
JP2019519592A (ja) * 2016-06-29 2019-07-11 メンロ セラピューティクス インコーポレイテッド 様々な掻痒状態を処置するためのニューロキニン−１アンタゴニストの使用
US11957669B2 (en) 2017-08-11 2024-04-16 Amorepacific Corporation Pharmaceutical composition containing (R)-N-[1-(3,5-difluoro-4-methansulfonylamino-phenyl)-ethyl]-3-(2-propyl-6-trifluoromethyl-pyridin-3-yl)-acrylamide
CN114599364A (zh) 2019-09-05 2022-06-07 因赛特公司 用于减少特应性皮炎瘙痒的鲁索替尼制剂
WO2024117172A1 (ja) * 2022-11-30 2024-06-06 花王株式会社 痒みの予防又は改善剤
JP7478895B1 (ja) 2022-11-30 2024-05-07 花王株式会社 痒みの予防又は改善剤

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6203803B1 (en) 1994-12-14 2001-03-20 Societe L'oreal S.A. Use of a substance P antagonist in a cosmetic composition, and the composition thus obtained
FR2728265A1 (fr) 1994-12-19 1996-06-21 Oreal Utilisation d'un antagoniste de substance p dans une composition pharmaceutique
EP1295599A1 (en) 2001-09-21 2003-03-26 Boehringer Ingelheim International GmbH Method for the treatment of prevention of atopic dermatitis
GB0203020D0 (en) * 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
JP2006516581A (ja) * 2003-01-27 2006-07-06 グラクソ　グループ　リミテッド 機能性消化不良を治療するための化学化合物の使用
GB0522061D0 (en) 2005-10-28 2005-12-07 Glaxo Group Ltd Chemical process
HUE036548T2 (hu) * 2007-12-07 2018-08-28 Zymogenetics Inc IL-31-re specifikus humanizált antitest molekulák
GB0806652D0 (en) * 2008-04-11 2008-05-14 Glaxo Group Ltd Anhydrous crystal form of orvepitant maleate
EA201101207A1 (ru) * 2009-02-24 2012-04-30 Новартис Аг Применение антагонистов рецептора nk
WO2012121988A2 (en) * 2011-03-07 2012-09-13 Celgene Corporation Methods for treating diseases using isoindoline compounds
PL2817312T3 (pl) 2012-02-22 2016-08-31 Leo Pharma As Nowe związki będące antagonistami receptora neurokininy 1
SG11201501867UA (en) * 2012-10-11 2015-04-29 Nerre Therapeutics Ltd Novel uses
US8906951B1 (en) 2013-06-24 2014-12-09 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus

Also Published As

Publication number Publication date
HRP20191955T1 (hr) 2020-01-24
JP2019131594A (ja) 2019-08-08
KR20150064732A (ko) 2015-06-11
RS59470B1 (sr) 2019-11-29
IL237636A0 (en) 2015-04-30
US20190216806A1 (en) 2019-07-18
HK1211486A1 (en) 2016-05-27
MX362879B (es) 2019-02-21
EP2906219A1 (en) 2015-08-19
PT2906219T (pt) 2019-11-04
JP6953468B2 (ja) 2021-10-27
AU2013328695B2 (en) 2018-04-05
CY1122313T1 (el) 2021-01-27
US9603849B2 (en) 2017-03-28
JP2015533136A (ja) 2015-11-19
CA2884454C (en) 2021-07-27
KR102202481B1 (ko) 2021-01-12
HUE046508T2 (hu) 2020-03-30
AU2013328695A9 (en) 2018-04-26
LT2906219T (lt) 2019-10-25
AU2013328695B9 (en) 2018-05-17
PL2906219T3 (pl) 2020-02-28
EP2906219B1 (en) 2019-08-07
US20170143711A1 (en) 2017-05-25
AU2013328695A1 (en) 2015-04-02
EA201590364A1 (ru) 2015-11-30
IL237636B (en) 2019-01-31
MX2015004162A (es) 2015-07-06
ES2750662T3 (es) 2020-03-26
EP3597192A1 (en) 2020-01-22
CA2884454A1 (en) 2014-04-17
WO2014057003A1 (en) 2014-04-17
DK2906219T3 (da) 2019-10-28
SI2906219T1 (sl) 2019-12-31
CN104703603A (zh) 2015-06-10
US20150238486A1 (en) 2015-08-27
JP6815728B2 (ja) 2021-01-20
SG11201501867UA (en) 2015-04-29

Similar Documents

Publication Publication Date Title
BR112015006051A2 (pt) usos inéditos
BR112017002811A2 (pt) compostos de pirrolopirimidina usados como agonista de tlr7
NI201500167A (es) Compuestos químicos
CL2015001864A1 (es) Compuestos derivados de espiropirido[1,2-a]pirazina sustituidos, como inhibidores de la integrasa del vih; composicion farmaceutica que los comprende; y su uso para la profilaxis o el tratamiento de una infeccion por vih.
EA201400986A1 (ru) Фармацевтические композиции, содержащие метформин и ингибитор dpp-4 или ингибитор sglt-2
DOP2013000192A (es) Compuestos y composiciones como inhibidores de la trk
BR112017013440A2 (pt) compostos de isoquinolina para o tratamento de hiv
BR102015032361A8 (pt) Compostos de quinazolina, usos dos mesmos, composição farmacêutica, kit e artigo de manufatura
UY35391A (es) Acido 2-aza-biciclo[2.2.1]heptano-3-carboxilico (bencil-cianometil)-amidas sustituidas inhibidores de catepsina c
UY36342A (es) Nuevos derivados de aminoalquilbenzotiazepinas y usos de los mismos
GT201400009A (es) 4-imidazopiridazin-1-il-benzamidas y 4-imidazotriazin-1-il-benzamidas como inhibidores de btk
BR112019003932A2 (pt) composto, composição farmacêutica, combinação, método de tratamento de uma doença ou desordem e uso do composto
BR112015011036A2 (pt) derivados de 2-amino-quinazolina substituídos heterocíclicos para o tratamento de infecções virais
BR112014030386A8 (pt) Compostos e composições para modular a atividade de egfr
BR112014019171A8 (pt) Composições intranasais de dexdetomida e seus métodos de uso
BR112015007061A8 (pt) composto, composição farmacêutica e uso do composto
CO2018002211A2 (es) Piridinona dicarboxamida para su uso como inhibidores de bromodominio
NI201500096A (es) Compuesto químicos
CR20130602A (es) Compuestos novedosos como inhibidores de diacilglicerol aciltransferasa
GT201600027A (es) Inhibidores de rorc2 y sus métodos de uso
BR112017006085A2 (pt) compostos 1-alquil-6-oxo-1,6-di-hidropiridin-3-ila e uso como moduladores sgrm
BR112017000246A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal
BR112016013116A2 (pt) Inibidores de trifluorometil pirazolil guanidina f1f0-atpase, seus usos, e composições farmacêuticas
CL2014001862A1 (es) Compuestos derivados de morofolinilo sustituido, útiles como inhibidores de mogat-2; composicion farmaceutica que los comprende; uso en el tratamiento de hipertrigliceridemia.
BR112014030720A8 (pt) composto, composição farmacêutica e usos de inibidores de fbx03

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]